Aligos Therapeutics, Inc. (ALGS) |
|
1.31 -0.03 (-2.24%)
|
06-26 19:18 |
|
Open: |
1.38 |
Pre. Close: |
1.34 |
|
High:
|
1.38 |
Low:
|
1.28 |
|
Volume:
|
1,903,595 |
Market Cap:
|
56(M) |
|
|
|
|
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.38 - 1.39 |
1.39 - 1.39 |
|
Low:
|
1.26 - 1.27 |
1.27 - 1.28 |
|
Close:
|
1.3 - 1.31 |
1.31 - 1.32 |
|
Technical analysis |
as of: 2022-06-24 4:37:56 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 1.65  One year: 1.92 |
| Support: |
Support1: 1.02 Support2: 0.85 |
| Resistance: |
Resistance1: 1.41 Resistance2: 1.64 |
| Pivot: |
1.32 |
| Moving Average: |
MA(5): 1.23  MA(20): 1.3
MA(100): 1.82 MA(250): 8.9 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 32.7 %D(3): 23 |
| RSI: |
RSI(14): 51.1 |
| 52-week: |
High: 18.23 Low: 1.02 |
| Average Vol(K): |
3-Month: 358 (K) 10-Days: 410 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ALGS ] has closed above bottom band by 47.3%. Bollinger Bands are 14% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Sun, 26 Jun 2022
How to watch the ALGS Championship 2022 - Upcomer
Fri, 24 Jun 2022
Do Analysts Expect Aligos Therapeutics Inc (ALGS) Stock to Rise After It Is Up 12.61% in a Month? - InvestorsObserver
Fri, 24 Jun 2022
Mirum Pharmaceuticals (MIRM) Highlights Data Demonstrating Impact of LIVMARLI - StreetInsider.com
Thu, 16 Jun 2022
Apex pros with COVID may be barred from playing in ALGS Championship, players say - Dot Esports
Tue, 14 Jun 2022
Monitoring Nutrition and Progression of ALGS - MD Magazine
Tue, 14 Jun 2022
Using Maralixibat for the Management of Pediatric ALGS - MD Magazine
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
40 (M) |
|
% Held by Insiders
|
1.824e+007 (%) |
|
% Held by Institutions
|
16.5 (%) |
|
Shares Short
|
2,410 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.3318e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-2 |
|
Return on Assets (ttm)
|
261.4 |
|
Return on Equity (ttm)
|
-38.3 |
|
Qtrly Rev. Growth
|
6.02e+006 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0.1 |
|
EBITDA (p.s.)
|
-3.08 |
|
Qtrly Earnings Growth
|
-3.4 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-106 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
12.97 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
2.9e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
